Niels van de Donk
Niels van de Donk
Associate Professor of Hematology, VU University Medical Center
Потвърден имейл адрес: vumc.nl
Targeting CD38 with daratumumab monotherapy in multiple myeloma
HM Lokhorst, T Plesner, JP Laubach, H Nahi, P Gimsing, M Hansson, ...
New England Journal of Medicine 373 (13), 1207-1219, 2015
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group
P Sonneveld, H Avet-Loiseau, S Lonial, S Usmani, D Siegel, ...
Blood, The Journal of the American Society of Hematology 127 (24), 2955-2962, 2016
Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
J Krejcik, T Casneuf, IS Nijhof, B Verbist, J Bald, T Plesner, K Syed, K Liu, ...
Blood, The Journal of the American Society of Hematology 128 (3), 384-394, 2016
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA …
P Moreau, M Attal, C Hulin, B Arnulf, K Belhadj, L Benboubker, MC Béné, ...
The Lancet 394 (10192), 29-38, 2019
International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment
MA Dimopoulos, P Sonneveld, N Leung, G Merlini, H Ludwig, E Kastritis, ...
Journal of Clinical Oncology 34 (13), 1544-1557, 2016
European Myeloma Network guidelines for the management of multiple myeloma-related complications
E Terpos, M Kleber, M Engelhardt, S Zweegman, F Gay, E Kastritis, ...
haematologica 100 (10), 1254, 2015
CD38 antibodies in multiple myeloma: back to the future
NWCJ van de Donk, PG Richardson, F Malavasi
Blood, The Journal of the American Society of Hematology 131 (1), 13-29, 2018
Monoclonal antibodies targeting CD 38 in hematological malignancies and beyond
NWCJ van de Donk, ML Janmaat, T Mutis, JJ Lammerts van Bueren, ...
Immunological reviews 270 (1), 95-112, 2016
International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders
J Hillengass, S Usmani, SV Rajkumar, BGM Durie, MV Mateos, S Lonial, ...
The lancet oncology 20 (6), e302-e312, 2019
CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma
IS Nijhof, T Casneuf, J Van Velzen, B van Kessel, AE Axel, K Syed, ...
Blood, The Journal of the American Society of Hematology 128 (7), 959-970, 2016
Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study
SK Kumar, MA Dimopoulos, E Kastritis, E Terpos, H Nahi, H Goldschmidt, ...
Leukemia 31 (11), 2443-2448, 2017
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma
M Engelhardt, E Terpos, M Kleber, F Gay, R Wäsch, G Morgan, M Cavo, ...
haematologica 99 (2), 232, 2014
Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab
IS Nijhof, RWJ Groen, HM Lokhorst, B Van Kessel, AC Bloem, ...
Leukemia 29 (10), 2039-2049, 2015
Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma
NWCJ van de Donk, P Moreau, T Plesner, A Palumbo, F Gay, JP Laubach, ...
Blood, The Journal of the American Society of Hematology 127 (6), 681-695, 2016
CD38 antibodies in multiple myeloma: mechanisms of action and modes of resistance
NWCJ Van de Donk, SZ Usmani
Frontiers in immunology 9, 2134, 2018
A rational strategy for reducing on-target off-tumor effects of CD38-chimeric antigen receptors by affinity optimization
E Drent, M Themeli, R Poels, R de Jong-Korlaar, H Yuan, J de Bruijn, ...
Molecular therapy 25 (8), 1946-1958, 2017
The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma
HM Lokhorst, K Wu, LF Verdonck, LL Laterveer, NWCJ van de Donk, ...
Blood 103 (11), 4362-4364, 2004
Preclinical evidence for the therapeutic potential of CD38-targeted immuno-chemotherapy in multiple myeloma patients refractory to lenalidomide and bortezomib
IS Nijhof, RWJ Groen, WA Noort, B van Kessel, R de Jong-Korlaar, ...
Clinical cancer research 21 (12), 2802-2810, 2015
How I treat plasma cell leukemia
NWCJ van de Donk, HM Lokhorst, KC Anderson, PG Richardson
Blood, The Journal of the American Society of Hematology 120 (12), 2376-2389, 2012
Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma
T Casneuf, XS Xu, HC Adams III, AE Axel, C Chiu, I Khan, T Ahmadi, ...
Blood advances 1 (23), 2105-2114, 2017
Системата не може да изпълни операцията сега. Опитайте отново по-късно.
Статии 1–20